RxSight (RXST) Net Cash Flow Growth (1y) (2021 - 2026)
RxSight (RXST) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -31.84% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 76.43% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -394.13% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn | -121.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121.08% |
| Dec 31, 2025 | -26,952.78% |
| Sep 30, 2025 | -38.66% |
| Jun 30, 2025 | 250.52% |
| Mar 31, 2025 | -50.83% |
| Dec 31, 2024 | 120.81% |
| Sep 30, 2024 | -830.12% |
| Jun 30, 2024 | -262.79% |
| Mar 31, 2024 | 2,886.04% |
| Dec 31, 2023 | -106.05% |
| Sep 30, 2023 | 107.02% |
| Jun 30, 2023 | -107.64% |
| Mar 31, 2023 | 97.25% |
| Dec 31, 2022 | 106.55% |
| Sep 30, 2022 | -156.81% |
| Jun 30, 2022 | 69.67% |
| Mar 31, 2022 | -388.04% |
| Dec 31, 2021 | -2,854.83% |
| Sep 30, 2021 | 5,507.54% |